ライフサイエンスコーパス: oropharyngeal cancer

1 papillomavirus (HPV) infection is a cause of oropharyngeal cancer.

2 L are important adjuncts to the treatment of oropharyngeal cancer.

3 may have implications in the development of oropharyngeal cancer.

4 luate associations between HPV infection and oropharyngeal cancer.

5 in patients following radiation therapy for oropharyngeal cancer.

6 tion, are associated with increased risk for oropharyngeal cancer.

7 taining mouthwashes may increase the risk of oropharyngeal cancer.

8 ke and tobacco use are established causes of oropharyngeal cancer.

9 e outcomes for patients with newly diagnosed oropharyngeal cancer.

10 of oral microbiome with oral HPV, a cause of oropharyngeal cancer.

11 HPV DNA or RNA status in some patients with oropharyngeal cancer.

12 d-of-care treatment option for patients with oropharyngeal cancer.

13 nd laryngeal cancers, but not for those with oropharyngeal cancer.

14 men who may be at higher risk of developing oropharyngeal cancer.

15 ising cancer biomarkers for the prognosis of oropharyngeal cancer.

16 and the oral microbiome are associated with oropharyngeal cancer.

17 etter prognosis than patients with p16-/HPV- oropharyngeal cancer.

18 py is an integral component of treatment for oropharyngeal cancer.

19 nce of human papillomavirus (HPV)-associated oropharyngeal cancer.

20 rade 3, and 5.51 (95% CI, 1.22 to 24.84) for oropharyngeal cancer.

21 evelop a TNM classification specific to HPV+ oropharyngeal cancer.

22 derive new staging classifications for HPV+ oropharyngeal cancer.

23 ical cancer and a major cause of genital and oropharyngeal cancer.

24 , the presumed precursor of HPV16-associated oropharyngeal cancer.

25 s and pathways significantly associated with oropharyngeal cancer.

26 virus (HPV) develop HPV-related cervical and oropharyngeal cancer.

27 ecognized as important causative factors for oropharyngeal cancer.

28 ded (IGRT) radiotherapy for locally advanced oropharyngeal cancer.

29 finger protein genes on chromosome 19q13 in oropharyngeal cancer.

30 stic factor for survival among patients with oropharyngeal cancer.

31 revealing the potential infectious nature of oropharyngeal cancer.

32 are associated with a growing percentage of oropharyngeal cancers.

33 r p16-negative (HR, 1.33; 95% CI, 0.96-1.86) oropharyngeal cancers.

34 tiological agents for several anogenital and oropharyngeal cancers.

35 PVs) are causative agents in ano-genital and oropharyngeal cancers.

36 ly HPV16, are major causes of anogenital and oropharyngeal cancers.

37 particularly HPV16, can cause anogenital and oropharyngeal cancers.

38 types including vaginal, vulvar, penile, and oropharyngeal cancers.

39 s (HPVs) are a major cause of anogenital and oropharyngeal cancers.

40 ruses (HPVs) cause cervical, anogenital, and oropharyngeal cancers.

41 worldwide, notably cervical, anogenital, and oropharyngeal cancers.

42 reas HPV16 dominates in other anogenital and oropharyngeal cancers.

43 irus (HPV) infections are a leading cause of oropharyngeal cancers.

44 vity cancers while HPV is the major cause of oropharyngeal cancers.

45 tained current data for HPV-related oral and oropharyngeal cancers.

46 a major cause of noncervical anogenital and oropharyngeal cancers.

47 intensity-modulated radiotherapy (IMRT) for oropharyngeal cancers.

48 fection, the principal cause of HPV-positive oropharyngeal cancers.

49 pe associated with cervical, anogenital, and oropharyngeal cancers.

50 ive agents of cervical, anal as well as many oropharyngeal cancers.

51 and reducing the morbidity of treatments for oropharyngeal cancers.

52 ausative agents of anogenital tract and some oropharyngeal cancers.

53 ers and a proportion of other anogenital and oropharyngeal cancers.

54 an papillomavirus (HPV)-associated anal than oropharyngeal cancers.

55 lomavirus (HPV) infection causes a subset of oropharyngeal cancers.

56 esent more than 10 years before diagnosis of oropharyngeal cancers.

57 A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumor

58 One patient with oropharyngeal cancer (3.3%), who was recurrence-free pre

59 Of 1907 patients with HPV+ oropharyngeal cancer, 661 (35%) were recruited at the tr

60 cancer site were seen for hypopharyngeal and oropharyngeal cancers (-$703/mo; 95% CI, -$967 to -$439)

61 (47 of 51 [92.2%]) compared to patients with oropharyngeal cancer (85 of 110 [77.3%]).

62 dence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patien

63 The increased risk of oropharyngeal cancer among HPV16 E6 seropositive partici

64 L1 seropositivity was highly associated with oropharyngeal cancer among subjects with a history of he

65 al HPV infection is strongly associated with oropharyngeal cancer among subjects with or without the

66 also related to the increasing incidence of oropharyngeal cancer among young men.

67 al oncogenic HPV infections and HPV-positive oropharyngeal cancers among men than women arises in par

68 iagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95%

69 l study of 100 patients with newly diagnosed oropharyngeal cancer and 200 control patients without ca

70 strongly associated with the development of oropharyngeal cancer and a small minority of oral cavity

71 (aged >=18 years) with stage III or stage IV oropharyngeal cancer and an Eastern Cooperative Oncology

72 PK pathway was significantly associated with oropharyngeal cancer and cervical cancer, and TGFbetaR1

73 TGFbeta signaling in the development of both oropharyngeal cancer and cervical cancer.

74 n papillomavirus (HPV) is the major cause of oropharyngeal cancer and encodes three known oncoprotein

75 s been implicated in the rising incidence of oropharyngeal cancer and has led to variety of studies e

76 human papillomavirus 16 (HPV16) and HPV18 in oropharyngeal cancer and hepatitis B and C viruses in li

77 d genes is associated with susceptibility to oropharyngeal cancer and implicates TGFbetaR1/TGFbeta si

78 The rate of de novo oropharyngeal cancer and lung cancer was 25.5 times and

79 e recurrence in patients with HPV-associated oropharyngeal cancer and may facilitate earlier initiati

80 genes is a determinant of susceptibility to oropharyngeal cancer and other HPV-associated cancers by

81 ohol consumption with respect to the risk of oropharyngeal cancers and cancers of the upper aerodiges

82 e the causative agents of genital as well as oropharyngeal cancers and exhibit enhanced amounts of DN

83 A total of 84% of the patients had oropharyngeal cancer, and 75% had tumor specimens that s

84 worse prognosis than patients with p16+/HPV+ oropharyngeal cancer, and a significantly better prognos

85 incidence data for cervical adenocarcinoma, oropharyngeal cancer, and anal cancer.

86 a significant challenge in the treatment of oropharyngeal cancer, and given practical limitations of

87 can cause cervical and other anogenital and oropharyngeal cancer, and other types of HPV are associa

88 cers, 6,832 other oral cavity cancers, 9,373 oropharyngeal cancers, and 200,000 controls) within the

89 ely to receive immunotherapy than those with oropharyngeal cancer (AOR, 1.29 [95% CI, 1.05-1.59]), as

90 mely, and cost-effective methods for staging oropharyngeal cancers are crucial for patient prognosis

91 Oropharyngeal cancer associations were limited to the hu

92 ted using data from 447 patients treated for oropharyngeal cancer at Erasmus Medical Center in the Ne

93 omising prevention tools for oral cavity and oropharyngeal cancers at this time.

94 owing difficulty after radiation therapy for oropharyngeal cancer based on radiation dose to various

95 000 cancer cases annually, with cervical and oropharyngeal cancer being the two most prominent types.

96 ength and consistency of HPV DNA presence in oropharyngeal cancers bolster the argument that this ass

97 ogenesis in a large majority of HPV-positive oropharyngeal cancers by inducing extensive disruption o

98 mproves the clinical evaluation of suspected oropharyngeal cancers by providing higher diagnostic cer

99 Analysis of 105 HPV-positive oropharyngeal cancers by whole-genome sequencing detects

100 l cancer, and TGFbetaR1 was overexpressed in oropharyngeal cancer, cervical cancer, and HPV(+) head a

101 5% confidence interval (CI), 0.13-0.61] from oropharyngeal cancer, closely followed by high viral loa

102 HPV status was determined for all 271 oropharyngeal cancers collected by the three population-

103 that mouthwash does not increase the risk of oropharyngeal cancer, confounding due to underascertaine

104 tier integrative computational analysis with oropharyngeal cancer data from a head and neck cancer ge

105 is with a primary squamous cell carcinoma of oropharyngeal cancer; data on p16 immunohistochemistry a

106 r sexual behaviors that elevated the odds of oropharyngeal cancer developing in a case-control study

107 tivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in

108 xample, why does the increase in HPV-related oropharyngeal cancer dominate in men?

109 patients with human papillomavirus-positive oropharyngeal cancer enrolled in a phase II trial who un

110 e time, introduced several novel concepts in oropharyngeal cancer epidemiology that remain relevant t

111 Blot and colleagues represents a landmark in oropharyngeal cancer epidemiology.

112 Oropharyngeal cancer exhibited more variable 2-year surv

113 We analysed 1373 patients with oropharyngeal cancer from May 9, 2020, to Nov 22, 2023.1

114 study included patients with non-metastatic oropharyngeal cancer from seven cancer centres located a

115 ividual data for 13 cohorts of patients with oropharyngeal cancer from the UK, Canada, Denmark, Swede

116 e part of the Human Papillomavirus, Oral and Oropharyngeal Cancer Genomic Research (VOYAGER) consorti

117 HPV-positive oropharyngeal cancers harbor few mutations in the Hippo

118 ence of human papilloma virus (HPV)-positive oropharyngeal cancers has risen rapidly in recent decade

119 Oral and oropharyngeal cancer have low survival rates, and incide

120 le in curative human papillomavirus-positive oropharyngeal cancer (HPV+ OPC) remains undefined.

121 for the early detection of HPV-attributable oropharyngeal cancer (HPV-AOC) and potentially other HPV

122 Human papillomavirus (HPV)-attributable oropharyngeal cancer (HPV-OPC) incidence is increasing i

123 HPV attributable oropharyngeal cancer (HPV-OPC) incidence is increasing i

124 nt protocols for human papillomavirus-driven oropharyngeal cancer (HPV-OPC) is that few predictors of

125 ents are particularly needed for HPV-related oropharyngeal cancers (HPV(+)OPCs) whose incidence is in

126 tigens in human papillomavirus (HPV)-related oropharyngeal cancer (HPVOPC) are attractive targets for

127 Human papilloma virus-16 (HPV-16) associated oropharyngeal cancer (HPVOPC) is increasing alarmingly i

128 P < 0.0001); for patients with HPV-positive oropharyngeal cancer, HR was 24.1 (95% CI 3.0-196.8; P <

129 omarker assay for inferring HPV causation in oropharyngeal cancer in clinical and trial settings.

130 curve (AUC) were 0.70 or higher, except for oropharyngeal cancer in men.

131 cases) and anal cancers (16%) in females and oropharyngeal cancers in males (20%).

132 -intensification regimens for HPV-associated oropharyngeal cancers in populations with high tobacco c

133 infection is causing an increasing number of oropharyngeal cancers in the United States and Europe.

134 Today, more than 80% of oropharyngeal cancers in the United States are caused by

135 ecent increases in incidence and survival of oropharyngeal cancers in the United States have been att

136 e population-level incidence and survival of oropharyngeal cancers in the United States since 1984 ar

137 papillomavirus (HPV) causes the majority of oropharyngeal cancers in the United States, yet the risk

138 Human papillomavirus-associated oropharyngeal cancer, in particular, is increasing in in

139 Oropharyngeal cancer incidence is rapidly rising due to

140 Many prognostic algorithms for oropharyngeal cancer incorporate HPV status as a stratif

141 this prognostic study, a multistate model of oropharyngeal cancer incorporating imaging biomarkers ap

142 Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to

143 Human papillomavirus-related (HPV+) oropharyngeal cancer is a rapidly emerging disease with

144 By contrast, tobacco-related oropharyngeal cancer is characterised by TP53 mutation a

145 The biology of HPV-positive oropharyngeal cancer is distinct with P53 degradation, r

146 Our proposed ICON-S staging system for HPV+ oropharyngeal cancer is suitable for the 8th edition of

147 continue, the annual number of HPV-positive oropharyngeal cancers is expected to surpass the annual

148 dence of human papillomavirus (HPV)-positive oropharyngeal cancers is higher and increasing more rapi

149 independent causal effect of smoking on oral/oropharyngeal cancer (IVW OR 2.6, 95% CI = 1.7, 3.9 per

150 with a truncated COOH-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p

151 ts with p16-positive locoregionally advanced oropharyngeal cancer (LA-OPC).

152 he biologic characteristics and treatment of oropharyngeal cancer may help inform improvements in pro

153 Among 806 patients with oropharyngeal cancer (mean [SD] age, 63.6 [10.6] years;

154 Oropharyngeal cancers (n=7) were found to be 7.6 times h

155 institutions (International Collaboration of Oropharyngeal Cancer Network for N-Classification [ICON-

156 The International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) aimed

157 was the 2016 International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S) study.

158 d system, the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S); and a

159 18 years or older with HPV-positive low-risk oropharyngeal cancer (non-smokers or lifetime smokers wi

160 ex partners (26 or more) was associated with oropharyngeal cancer (odds ratio, 3.1; 95% confidence in

161 Among people with oropharyngeal cancer only, HPV status was associated wit

162 In 2017, 46,157 and 3,127 new oropharyngeal cancer (OPC) cases were reported in the U.

163 ents with human papillomavirus (HPV)-related oropharyngeal cancer (OPC) generally present with more a

164 g rates of human papillomavirus (HPV)-driven oropharyngeal cancer (OPC) have largely offset declines

165 rasts in HPV-attributable fractions (AFs) in oropharyngeal cancer (OPC) have not been evaluated in de

166 en identified as the cause of the increasing oropharyngeal cancer (OPC) incidence in some countries.

167 Human papillomavirus (HPV)-related oropharyngeal cancer (OPC) incidence is increasing among

168 Oropharyngeal cancer (OPC) incidence is rising among men

169 iation with or without chemotherapy to treat oropharyngeal cancer (OPC) is supported by evidence from

170 To improve risk prediction for oropharyngeal cancer (OPC) patients using cluster analys

171 stomia, we conducted a GWAS of 359 long-term oropharyngeal cancer (OPC) survivors using 579,956 autos

172 Although several oropharyngeal cancer (OPC) susceptibility loci have been

173 life and may deteriorate substantially after oropharyngeal cancer (OPC) treatment.

174 is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC

175 diotherapy is the main treatment modality of oropharyngeal cancer (OPC), in which an accurate segment

176 deintensification in the management of p16+ oropharyngeal cancer (OPC).

177 cally in human papillomavirus (HPV)-mediated oropharyngeal cancer (OPC).

178 uman papillomavirus (HPV) is associated with oropharyngeal cancer (OPC).

179 nsible for the rising worldwide incidence of oropharyngeal cancer (OPC).

180 ave achieved limited success in HPV-positive oropharyngeal cancer (OPC).

181 is the principal cause of a distinct form of oropharyngeal cancer (OPCA) that has been rising in inci

182 The incidence of oropharyngeal cancer (OPSCC) has escalated in the past f

183 cancers (ORs, 1.8 [95% CI, 1.5 to 2.3]) and oropharyngeal cancer (OR, 1.3 [95% CI, 1.0 to 1.6]) and

184 women were over-represented among women with oropharyngeal cancer (OR, 3.2; 95% CI, 1.7 to 6.0).

185 ic target for HPV-driven cervical, anal, and oropharyngeal cancers over the last two decades.

186 Patients with discordant oropharyngeal cancer (p16-/HPV+ or p16+/HPV-) had a sign

187 For oropharyngeal cancer, p16-positive patients had better O

188 In the US, oropharyngeal cancer, predominantly caused by high-risk

189 d alcohol use increased the association with oropharyngeal cancer primarily among subjects without ex

190 Risk of oropharyngeal cancer progression and death increases dir

191 PV) integration into the host genome in oral/oropharyngeal cancer, reviewed the literature for HPV-in

192 associated with oral cavity cancer risk and oropharyngeal cancer risk, respectively.

193 portance of human leukocyte antigen loci for oropharyngeal cancer risk, suggesting that immunologic m

194 deviation in BMI [4.81kg/m(2)]) on oral and oropharyngeal cancer risk.

195 The management of recurrent oropharyngeal cancer (rOPC) is complex.

196 ssue (RR: 19.35 [17.44-21.47]) and lowest in oropharyngeal cancer (RR: 6.62 [5.61-7.81]).

197 HPV-positive oropharyngeal cancer seems to be more responsive to chem

198 HPV prevalence in oropharyngeal cancers significantly increased over calen

199 in a five-generation pedigree and comprises oropharyngeal cancer, skin telangiectases, and mild deve

200 ned to human papillomavirus (HPV)-associated oropharyngeal cancers, specifically the oropharynx subsi

201 ian males with advanced-stage HPV-associated oropharyngeal cancers suggests pervasive tobacco consump

202 survival rates in p16-positive patients with oropharyngeal cancer support the ongoing efforts to expl

203 ansform cells and contribute to cervical and oropharyngeal cancer, there clearly is much more to lear

204 onse to the growing burden of HPV-associated oropharyngeal cancer, this study investigated clearance

205 comprising 840 patients with newly diagnosed oropharyngeal cancer treated at a National Cancer Instit

206 to 75 years with stage III-IVB squamous cell oropharyngeal cancer treated with chemoradiotherapy were

207 rogates for overall survival in p16-positive oropharyngeal cancers treated with chemotherapy or radio

208 ampled blood from patients with stage III-IV oropharyngeal cancer undergoing concomitant chemoradioth

209 ll-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), fo

210 hin 5 months, while the 1-year mortality for oropharyngeal cancer was 57.1% and that for lung cancers

211 The proportion of patients with p16+/HPV- oropharyngeal cancer was highest in subsites outside the

212 Oropharyngeal cancer was significantly associated with o

213 ncurrent chemoradiation for locally advanced oropharyngeal cancers was conducted.

214 7895 patients with oropharyngeal cancer were assessed for eligibility.

215 wly biopsy-proven, untreated oral cavity and oropharyngeal cancer were enrolled.

216 This is particularly true for oropharyngeal cancers where the risk is more than 7 time

217 an papillomavirus (HPV) cause anogenital and oropharyngeal cancers, whereas cutaneous types (e.g. HPV

218 V) from the genus alpha cause anogenital and oropharyngeal cancers, whereas the contribution of HPV f

219 d by the fact that the patient had developed oropharyngeal cancer, which was treated with chemoradiot

220 V-16) and HPV-18 cause a large proportion of oropharyngeal cancers, which are increasing in incidence

221 rank alcohol, and 113 (65.7%) presented with oropharyngeal cancers, which were positive for human pap

222 sessing definitive treatment of p16-positive oropharyngeal cancer with chemotherapy or radiotherapy.

223 bserved HPV prevalence was reweighted to all oropharyngeal cancers within the cancer registries to ac